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ABSTRACT
Background and Objectives: The aim of this study was to evaluate the efficacy of lacidipine in reducing blood pressure (BP) 
and to determine its effect on endothelial function in mild-to-moderate hypertensive patients with type 2 diabetes mellitus 
(DM). Subjects and Methods: This was a prospective, multicenter, open-label, single-arm study, enrolling 290 patients 
with mild-to-moderate hypertension and type 2 DM. Patients were initially treated with 2 mg lacidipine orally once daily for 
4 weeks, which was then increased as necessary every 4 weeks to a maximal dose of 6 mg daily. The primary endpoint was the 
mean change in systolic blood pressure (SBP) from baseline after 12 weeks of treatment. Secondary endpoints included mean 
changes in diastolic blood pressure (DBP), flow-mediated vasodilatation (FMD), and serum concentrations of biochemical 
markers such as high-sensitivity C-reactive protein (hs-CRP), monocyte chemo-attractant protein-1 (MCP-1), matrix metal-
loproteinase-9 (MMP-9), and plasminogen activator inhibitor-1 (PAI-1). Results: Lacidipine treatment significantly reduced 
SBP by -13.4±13.0 mmHg (p<0.001) and DBP by -6.2±9.3 mmHg (p<0.001). Lacidipine treatment did not improve endothe-
lial-dependent vasodilatation, despite significantly improved nitroglycerin-induced, endothelial-independent vasodilatation. 
MCP-1 levels significantly decreased from 283.66±110.08 pg/mL to 257.83±100.23 pg/mL (p<0.001); whereas there were no 
significant changes in the levels of hs-CRP, MMP-9, or PAI-1. Conclusion: Twelve weeks of treatment with lacidipine was ef-
fective and well tolerated in mild-to-moderate hypertensive patients with type 2 DM. In spite of inducing a significant reduc-
tion in MCP-1 levels, lacidipine did not improve endothelial function. (Korean Circ J 2010;40:632-638)
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Introduction 
The prevalence of hypertension in patients with diabetes 
mellitus (DM) is extremely high (20-60%).
1) Moreover, comor-
bid hypertension has been widely reported to increase the risk 
of cardiovascular events, which account for 86% of the deaths 
occurring among patients with DM; it is also known to in-
crease the incidence of microvascular complications. How-
ever, it has been reported that only 28% of diabetic patients 
have adequately controlled blood pressure (BP) under 130/80 
mmHg.
2) This control rate is even lower (21.6%) among Ko-
rean patients.
3) Although recent guidelines recommend an-
giotensin receptor antagonists or angiotensin-converting enzy-
me inhibitors as frontline antihypertensive agents in patients 
with DM, most patients eventually require more than 2 classes 
of antihypertensive agents to achieve target BP.
4) 
Lacidipine, a long-acting dihydropyridine calcium channel 
blocker, has been reported to reverse endothelial dysfunction,
5) 
and to cause regression of atherosclerosis.
6) The European La-
cidipine Study on Atherosclerosis demonstrated that 4 years 
of lacidipine treatment retarded the progression of athero-
sclerosis more effectively than atenolol. Investigators suggest-
ed that this effect was due to restoration of endothelial func-
tion and reduction in oxidative stress.
7) 
However, the effects of lacidipine in type 2 DM patients have 
been only reported from small-scale, nonblinded studies.
8) Fur-
thermore, there is a paucity of data regarding the effects of la-
cidipine on endothelial dysfunction, which is observed in most 
patients with DM.
In this study, we evaluated the efficacy of lacidipine in reduc-
ing BP, as well as its effect on endothelial function, in mild-to-
moderate hypertensive patients with type 2 DM. 
Subjects and  Methods
Study population
A subject was only eligible for inclusion in this study if all 
the following criteria applied: 1) male or female 35 to 75 years 
of age at screening, 2) newly diagnosed essential hypertension 
or essential hypertension untreated in the 2 months prior to 
screening, and 3) type 2 DM (ADA criteria 2004). Any sub-
jects taking antihypertensive medications had to undergo a 
2-week washout period before enrollment. The definition of 
hypertension was a sitting systolic blood pressure (SiSBP) of 
≥130 mmHg, measured with a BP cuff, because the SBP goal 
is less than 130 mmHg in patients with diabetes. Exclusion 
criteria were as follows: severe hypertension with SiSBP >180 
mmHg; or any serious disorder that could limit the ability of 
the patient to participate in the study, including severe coro-
nary artery disease, uncontrolled DM (hemoglobin A1C >11%), 
or secondary hypertension.
Study design
This was a multicenter, open-label, single-arm study per-
formed at 20 sites in the Republic of Korea. The study proto-
col was approved by the institutional review board at each 
site. Before entering the study, patients provided written, in-
formed consent. A medical history was obtained during the 
screening phase, and a physical examination, 12-lead electro-
cardiogram, complete blood count, serum biochemistry, and 
routine urinalysis were performed at each center. During the 
12-week treatment period, patients were initially treated with 
lacidipine 2 mg orally once daily for 4 weeks, and then were ti-
trated with increasing doses every 4 weeks to a maximal dose 
of 6 mg daily if the SiSBP did not decrease to <130 mmHg. 
Blood pressure measurement
At each visit, the SiSBP, sitting diastolic blood pressure (Si-
DBP), pulse rate, and body weight were recorded. To ensure 
consistency of trough values, these measurements were taken 
at the same time of day, before the next dose of lacidipine. At 
each center, a single investigator used the standard ausculta-
tory technique for measuring BP in each patient’s arm, using 
a mercury sphygmomanometer produced by one company 
(W. A. Baum Co. Inc, Copiague, NY, USA) and an appropri-
ately-sized BP cuff. 
Measurement of flow-mediated dilatation  
of the brachial artery 
The examination was conducted at each center by the same 
examiner throughout the study, using a standard technique.
9) 
Briefly, the diameter of the artery was measured using high-
resolution, 2-dimensional images obtained by ultrasound 
with a 7.5-MHz linear-array transducer. Subjects were asked 
not to smoke or drink coffee or tea for at least 2 hours before 
the scan was performed. The right brachial artery was scanned 
over a longitudinal section 3 to 5 cm above the right medial 
elbow for the first resting image. The diameter of the brachial 
artery was measured from the anterior to the posterior inter-
face between the media and adventitia (“m line”) at a fixed dis-
tance. 
The mean brachial artery diameter was calculated from 4 
cardiac cycles synchronized with R-wave peaks on the electro-
cardiography. A pneumatic tourniquet placed around the fo-
rearm distal to the target artery was then inflated to a pres-
sure of 250 mmHg, and inflation was maintained for 5 min-
utes. Increased flow was then induced by sudden cuff defla-
tion. A second scan was performed continuously for 60 se-
conds before, and for 120 seconds after cuff deflation. Then, 
15 minutes later, another resting image was recorded. A ni-
troglycerin tablet (0.4 mg) was then administered sublingually, 
and 3 minutes later the last scan was performed. All the im-
ages were stored in DICOM format for offline analysis, and 
then sent to the core laboratory. Two expert sonographers an-634   Lacidipine in Hypertension and Diabetes
alyzed all the images. Interobserver coefficients of variation 
for measuring vessel diameters at baseline, after hyperemia, and 
after nitroglycerin were 3.3±0.25%, 2.9±0.28%, and 3.5±0.22%, 
respectively.
 
Blood tests
Blood samples were collected after at least 12 hours of fast-
ing. Measurements of lipids, fasting glucose, and high-sensi-
tivity C-reactive protein (hs-CRP) were performed in the local 
laboratories at each center. Other serum biochemical markers 
were analyzed in the central, core laboratory of GSK Korea 
using commercially available enzyme-linked immunosorbent 
assay kits from various vendors as follows: monocyte chemo-
attractant protein-1 {(MCP-1); Bio-Rad Laboratories, Hercu-
les, CA, USA}, matrix metalloproteinase-9 {(MMP-9); Amer-
sham Biosciences, Uppsala, Sweden}, and plasminogen acti-
vator inhibitor-1 {(PAI-1); IMUBIND, American Diagnostica, 
Stamford, CT, USA}. 
 
Efficacy and safety variables
The primary efficacy variable in this study was the mean ch-
ange in trough SiSBP from baseline after 12 weeks of treat-
ment. Secondary efficacy variables included mean changes in 
SiDBP, flow-mediated dilatation (FMD), and biochemical mar-
kers such as hs-CRP, MCP-1, MMP-9, and PAI-1 after 12 weeks 
of treatment. 
Safety variables included the incidence of all adverse events 
(AEs), drug-related AEs, and the number of discontinuations. 
AEs were evaluated at each visit by physical examination and 
direct questioning. The seriousness of AEs and their relation 
to the study drugs were determined by the chief investigator 
at each center. The results of all laboratory tests were assessed 
by the investigators for clinical significance and for their pos-
sible relationship to the study drug.
Statistical analysis
Effectiveness was defined as >4.5 mmHg decrease in the 
mean SiSBP from baseline after 12 weeks. We calculated that 
321 patients would be required to fulfill the following pa-
rameters: standard deviation of 20 mmHg for SiSBP, overall 
1-sided significance of 0.05, 90% power, and 20% exclusion 
rate. In terms of absolute benefit, data from the per-protocol 
(PP) population were used for the main analysis and those 
from the intention-to-treat (ITT) population were used as a 
supplement. The ITT population was used primarily to evalu-
ate tolerability. 
 Continuous variables were analyzed using the t-test. Chan-
ges in BPs and serum markers were analyzed using a paired 
t-test. All statistical analyses were performed with Statistical 
Package for the Social Sciences (SPSS) 12.0 (SPSS Inc, Chica-
go, IL, USA), and p less than 0.05 were considered statistically 
significant. 
Results 
Baseline characteristics
A total of 333 patients were screened, and 290 patients (male : 
female=173 : 117) were enrolled in the study. Of them, 236 pa-
tients (81.4%) completed the study. The flow diagram of study 
patients is summarized in Fig. 1. Eighty subjects (33.9%) were 
treated with 2 mg of lacidipine throughout the study, 108 
(45.8%) were titrated up to 4 mg, and 48 (20.3%) were titrated 
up to 6 mg. 
The mean age in the study group was 56.6±9.2 (35-79) years, 
and 41% of the patients were over 60 years of age. The most 
common concomitant medications at baseline and during the 
study were oral hypoglycemic agents (75%), lipid-lowering 
agents (29%), antiplatelet agents (40%), and antacids (13%). 
The proportions of oral hypoglycemic agents were as follows: 
sulfonylureas 58%, biguanides 37%, alpha-glucosidase inhibi-
tors 13%, thiazolidinediones 14%, combination of more than 
two drugs 4%. 
 
Changes in blood pressure from baseline
In the PP population (n=236), SiSBP was significantly de-
creased by 13.4±13.0 mmHg (from 144.0±11.4 mmHg to 
130.6±12.5 mmHg, p<0.0001) after 12 weeks of treatment. 
In the ITT population (n=277), SiSBP also significantly de-
creased by 13.0±13.3 mmHg (from 144.2±12.3 mmHg to 
130.9±13.1 mmHg, p<0.0001) (Fig. 2). 
SiDBP decreased by 6.2±9.3 mmHg (from 88.7±8.8 mmHg 
to 82.5±9.0 mmHg, p<0.001) in the PP population and by 
6.1±9.1 mmHg (from 88.7±8.6 mmHg to 72.0±9.4 mmHg, 
p<0.001) in the ITT population. 
The overall response rate (SiSBP <130 mmHg) after 12 weeks 
of treatment was 58.5%. In the subgroup with baseline SiSBP 
greater than 140 mmHg (PP population, n=132), the change in 
n=333
Screened
n=43
Excluded from ITT analysis
Exclusion N
-Screening failure 36
-Baseline failure 07
n=290
ITT population 
n=236
Completed all studies 
(PP population)
n=54
Excluded from PP analysis 
Causes N
-Protocol violation 41
-Adverse event 09
-Other 04
Fig. 1. Flow diagram of study patients. ITT: intention to treat, FMD: 
flow-mediated dilatation, PP: per-protocol. Dae-Hee Kim, et al.   635
SiSBP was -18.1±13.3 mmHg (from 151.6±9.7 mmHg to 133.5± 
13.6 mmHg, p<0.001); whereas in the subgroup with baseline 
SiSBP less than 140 mmHg (n=104), the change in SiSBP was 
-7.5±9.8 mmHg (from 134.4±3.0 mmHg to 126.9±10.0 mmHg, 
p=0.03).
Changes in endothelial-dependent and 
endothelial-independent vasodilatation
Changes in endothelial-dependent vasodilatation of the 
brachial artery were analyzed in the PP population. The mean 
baseline percentage of endothelial-dependent vasodilatation 
was not related to baseline body mass index, lipids, serum bio-
markers, or SiSBP levels (Table 1). After 12 weeks of treatment 
with lacidipine, the percentage of endothelial-dependent va-
sodilatation changed from 5.22±4.91% to 5.52±4.92%, but this 
did not represent a statistically significant change (p=0.313). 
In contrast, endothelial-independent vasodilatation after ad-
ministration of sublingual nitroglycerin significantly increased 
from 13.94±7.21% to 14.97±7.42% (p=0.02). The baseline per-
centage of nitroglycerin-induced vasodilatation had a weak 
negative correlation with MCP-1 levels. All the subjects were 
divided into 2 subgroups. The FMD-responder group (n= 
130, 55.1%) included those patients who had increased en-
dothelial-dependent vasodilatation, and the FMD-nonre-
sponder group (n=106, 44.9%) included those patients who 
had no increase in endothelial-dependent vasodilatation. The 
FMD-responder group had significantly lower baseline tri-
glyceride (TG) levels (150±97 mg/dL vs. 185±156 mg/dL, p= 
0.02) and higher baseline high density lipoprotein-cholester-
ol (HDL-C) levels (46±11 mg/dL vs. 49±12 mg/dL, p=0.01) 
(Table 2).
 
Changes in blood chemistry and biomarkers
HbA1C and lipid profiles, including TGs, low density lipo-
protein-cholesterol, and HDL-C levels, did not change after 12 
weeks of lacidipine treatment. Among the biomarkers evalu-
ated, the plasma levels of MCP-1 significantly decreased from 
283.66±110.08 pg/mL to 257.83±100.23 pg/mL (p<0.001). 
In contrast, hs-CRP did not show any significant change (from 
0.51±1.07 mg/dL to 0.55±1.60 mg/dL, p=0.644). The results 
are presented in Table 2.
Tolerability
More than one AE event was reported in 40% of the pa-
tients in the ITT population (a total of 116 events in 290 pa-
tients). There were 105 events that were considered to be 
drug-related. The most common AEs thought to be drug-re-
lated were headache (n=16, 5.52%), palpitations (n=6, 2.07%), 
Fig. 2. Effect of lacidipine in mean sitting cuff- systolic blood pressure (SiSBP) in patients with mild- to- moderate hypertension after 4, 8, 
and 12 weeks of treatment. The mean change from baseline was significant in intention-to-treat (A) and per-protocol (B) groups (*p<0.001). 
LOCF: last observation carried forward. 
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Table 1. Correlation coefficients between various baseline values and vasorelaxation
 Baseline endothelial-dependent vasodilatation Baseline endothelial-independent vasodilatation
Correlation coefficient p Correlation coefficient p
BMI -0.037 0.573 -0.069 0.292
LDL-C -0.002 0.977 -0.147 0.52
TG  -0.035 0.588 -0.080 0.222
FBS -0.023 0.729 -0.096 0.142
HbA1c -0.002 0.975 -0.117 0.073
MCP-1 -0.058 0.379 -0.146 0.025*
hs-CRP -0.172 0.070 -0.041 0.530
MMP-9 -0.088 0.181 -0.014 0.828
PAI-1 -0.025 0.698 -0.053 0.414
Systolic BP -0.026 0.687 -0.025 0.703
BMI: body mass index, LDL-C: low density lipoprotein-cholesterol, TG: triglyceride, FBS: fasting blood glucose, MCP-1: monocyte chemoat-
tractant protein-1, MMP-9: matrix metalloproteinase-9, PAI-1: plasminogen activator inhibitor-1636   Lacidipine in Hypertension and Diabetes
facial flushing (n=5, 1.72%), dizziness (n=4, 1.38%), and chest 
pain (n=4, 1.38%). There were 11 severe AEs reported in 9 pa-
tients (3.10%). All of the severe events required hospitaliza-
tion, and included 2 cases of chest pain, and 1 case each of la-
ryngeal cancer, bladder cancer, back pain, hypoglycemia, he-
morrhoids, cerebral hemorrhage, depression, benign prostatic 
hyperplasia, and impaired glucose tolerance. All severe AEs 
were thought to be unrelated to drug therapy.
 
Discussion
This study was performed to evaluate the efficacy and tol-
erability of lacidipine in mild-to-moderate hypertensive pa-
tients with type 2 DM. To the best of our knowledge, this is 
the largest study evaluating the effect of calcium antagonists 
on endothelial function in hypertensive patients with DM. 
Lacidipine treatment effectively reduced SBP and DBP. 
When the dose was titrated up to 6 mg once daily, the over-
all response rate after 12 weeks of treatment reached 58.5%. 
Although this study did not have a comparative design, the 
extent of lacidipine-induced SiSBP reduction in our Korean 
population was comparable to the effects of lacidipine seen 
in other races,
10)11) as well as to the effects of other antihyper-
tensive agents, such as nifedipine,
12) atenolol,
13) thiazide,
14) is-
radipine,
15) and amlodipine
16) in Korean patients. 
The most interesting findings in this study were related to 
the role of lacidipine in the improvement of endothelial dys-
function in hypertensive patients with DM. Although a few 
Table 2. Baseline values and changes in the levels of glucose, lipids, serum markers, and SiSBP, stratified according to vasorelaxation
All
Endothelial-dependent vasodilatation  Endothelial-independent vasodilatation
Decreased (≤)
(n=130)
Increased (>)
(n=106)
Decreased (≤)
(n=141)
Increased (>)
(n=95)
HbA1C (%) 0 week 7.12±1.25 6.9±1.1 07.3±1.3* 7.1±1.3 07.1±10.2
12 weeks 7.15±1.31 6.9±1.1 07.3±1.4* 7.1±1.4 7.2±1.3
p NS NS NS NS NS
TG (mg/dL) 0 week 165±111 185±125 150±97* 157±940 171±122
12 weeks 166±115 183±141 153±86* 169±133 164±103
p NS NS NS NS NS
LDL-C (mg/dL) 0 week 112±32 110±320 113±330 117±330 108±320
12 weeks 112±31 111±290 113±330 114±290 111±320
p NS NS NS NS NS
HDL-C (mg/dL) 0 week 48±12 46±11 049±12* 45±10 *49±12*
12 weeks 49±13 46±10 051±14* 47±11 50±13
p NS NS NS NS NS
hs-CRP (mg/dL) 0 week 0.51±1.10 0.39±0.59 0.60±1.33 0.60±1.48 0.45±0.67
12 weeks 0.55±0.10 0.40±0.83 0.68±2.01 0.66±2.11 0.48±1.14
p NS NS NS NS NS
MCP-1 (pg/mL) 0 week 283.7±7.200 292.1±115.2 276.8±105.7 275.6±95.10 289.1±119.2
12 weeks 257.8±6.500 261.7±92.60 254.7±106.3 259.0±95.10 257.0±103.9
p <0.001 0.005 0.024 0.06 0.002
MMP-9 (pg/mL) 0 week 626.1±372.7 644.5±383.1 611.0±364.8 614.2±320.0 634.2±405.5
12 weeks 611.7±324.4 592.3±348.7 627.6±303.4 565.7±296.4 645.2±339.6
p NS NS NS NS NS
PAI-1 (pg/mL) 0 week 29.6±27.9 27.6±26.5 31.2±29.1 28.4±27.5 30.1±28.3
12 weeks 31.7±26.4 33.1±27.7 30.7±25.3 31.0±26.6 32.3±26.4
p NS NS NS NS NS
SiSBP (mmHg) 0 week 144.0±11.40 143.9±11.20 144.2±11.60 144.2±11.70 143.8±11.00
12 weeks 130.6±12.50 129.3±13.60 131.7±11.60 129.9±12.90 131.1±12.30
p <0.001 <0.001 <0.001 <0.001 <0.001
ΔSiSBP (mmHg) -13.5±13.0- -14.5±14.1- -12.5±12.00 -14.0±12.90 -13.1±12.30
*p<0.05 between the increase group and the no increase group. TG: triglyceride, LDL-C: low density lipoprotein-cholesterol, hs-CRP: high-
sensitivity CRP, MCP-1: monocyte chemoattractant protein-1, MMP-9: matrix metalloproteinase-9, PAI-1: plasminogen activator inhibitor-1, 
endothelial-independent vasodilatation group, SiSBP: sitting cuff-systolic blood pressure, ΔSiSBP: absolute amount of decrease in SiSBP Dae-Hee Kim, et al.   637
preclinical or small-scale clinical studies have suggested the 
beneficial effects of lacidipine on endothelial function in non-
diabetic subjects,
5) this is the first study evaluating the effects 
of lacidipine on endothelial function in diabetic patients with 
hypertension. Twelve weeks of lacidipine therapy did not im-
prove endothelial-dependent vasodilatation, despite the fact 
that endothelial-independent vasodilatation was significantly 
improved following administration of sublingual nitroglycer-
in. The lack of improvement in endothelial-dependent vaso-
dilatation stands in contrast to previous studies
5) which have 
shown an improvement in overall endothelial-dependent va-
sodilatation in nondiabetic patients. A number of mechanis-
ms may be invoked in understanding the discrepancy between 
our results and those in the nondiabetic population. Impair-
ment of endothelial-dependent vasodilatation is more severe 
in diabetic patients than it is in nondiabetic patients. Thus, 12 
weeks of treatment might not be sufficient for amelioration of 
this impairment. Impairment of endothelial-dependent vaso-
dilatation has been widely observed in arteries from diabetic 
animals,
17) as well as from normal animals exposed to hyper-
glycemia.
18) In such studies, endothelial-dependent vasodila-
tation had already been impaired while endothelial-indepen-
dent vasodilatation remained intact. Similarly, in a few animal 
studies,
19) as well as in human studies,
20) a diminished response 
to nitroglycerin was also observed in diabetes, which was pre-
ceded by a disturbed response to acetylcholine. Therefore, im-
paired vascular response to nitroglycerin is considered to oc-
cur at a more advanced stage of vascular dysfunction in dia-
betes. In this study, the baseline values of nitroglycerin-induc-
ed vasodilatation were more impaired than previously reported 
values of normal controls,
21) which also suggests that the pop-
ulation in this study might have had more advanced vascular 
dysfunction. Similarly, HMG-CoA reductase inhibitors (sta-
tins) have been shown to have significant beneficial effects 
on endothelial dysfunction in nondiabetic subjects.
22) How-
ever, many studies have also failed to show significant statin-
induced improvement in endothelial-dependent vasodilata-
tion in subjects with type 2 DM,
23) and only one report
21) has 
demonstrated statin-induced improvement in endothelial-
independent vasodilatation, as was shown in this study. 
In subgroup analysis, the group with increased endotheli-
al-dependent vasodilatation had lower TG levels and higher 
HDL-C levels. An elevated TG concentration may increase the 
levels of intracellular adhesion molecule-1  and vascular cell ad-
hesion molecule-1, which might result in increased inflam-
matory responses in endothelial cells.
24) Additionally, improve-
ment in endothelial dysfunction seems to be independent of 
BP-lowering effects, because there was no difference in the base-
line BP or the absolute amount of decrease in SBP between 
those with FMD improvement and those without improvement. 
Finally, we observed that the levels of MCP-1, a surrogate 
marker for inflammation,
25) significantly decreased after la-
cidipine treatment. The levels of MCP-1 in hypertensive pa-
tients have been reported to correlate with the severity of ca-
rotid intima-media thickness (IMT).
26) In this regard, decre-
ased MCP-1 concentrations following lacidipine treatment 
might be consistent with the previously reported anti-ath-
erosclerotic effect of lacidipine.
7) In this study by contrast, 
the levels of hs-CRP did not change significantly. This dis-
crepant result was consistent with that of a previous study in 
which patients with coronary artery disease had significantly 
reduced carotid IMT without a significant change in hs-CRP 
levels after 6 months of lacidipine treatment.
27) This discrep-
ancy between hs-CRP and MCP-1 has also been demonstrat-
ed in other studies of angiotensin receptor blockers.
28) 
Levels of PAI-1, a marker of fibrinolytic balance, did not de-
crease after lacidipine treatment. PAI-1 levels are elevated in 
subjects with risk factors for atherosclerosis and insulin resist-
ance.
29) PAI-1 expression is known to be regulated by nitiric ox-
ide (NO) activity, and therefore NO synthase activity.
30) In this 
regard, the lack of change in mean PAI-1 levels might be consist-
ent with the insignificant endothelial-dependent vasodilata-
tion changes observed in this study. 
There are several limitations to this study. First, this is a sin-
gle-arm, uncontrolled study. Owing to ethical concerns regard-
ing not administering antihypertensive therapy to patients with 
confirmed hypertension, we were unable to create a control gr-
oup. Second, the measurement and analysis of FMD could be 
observer-dependent with high variance. To reduce observer-de-
pendent bias, two expert sonographers in the core lab analyz-
ed all the images. Third, the measurements of lipids, fasting glu-
cose, and hs-CRP were performed by local laboratories at 
each center, and the results could vary between laboratories. 
However, the serum biochemical markers, including MCP-1, 
MMP-9, and PAI-1, were all analyzed in a single central labo-
ratory.
In summary, 12 weeks of lacidipine treatment was effective 
and well tolerated in diabetic patients with mild-to-moderate 
hypertension. Lacidipine partially improved vasorelaxation, 
which was associated with reduction in levels of inflammatory 
markers. 
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